Effects of Small Molecule Ligands on ACKR3 ReceptorsS

被引:3
|
作者
Hopkins, Brittany E. [1 ]
Masuho, Ikuo [5 ]
Ren, Dongjun [1 ]
Iyamu, Iredia D. [4 ]
Lv, Wei [4 ]
Malik, Neha [4 ]
Martemyanov, Kirill A. [5 ]
Schiltz, Gary E. [1 ,2 ,3 ,4 ]
Miller, Richard J. [1 ,6 ]
机构
[1] Northwestern Univ, Dept Pharmacol, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Dept Chem, Evanston, IL USA
[4] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Evanston, IL USA
[5] Scripps Res Inst Florida, Dept Neurosci, Jupiter, FL USA
[6] Lurie Res Bldg 8-125,303 East Super, Chicago, IL 60611 USA
关键词
CHEMOKINE RECEPTOR; FUNCTIONAL-ACTIVITY; BETA-ARRESTIN; CXCR7; MIGRATION; ACTIVATION; INHIBITION; CROSSTALK; TC14012; SIGNALS;
D O I
10.1124/molpharm.121.000295
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chemokines such as stromal derived factor 1 and their G pro-tein coupled receptors are well-known regulators of the devel-opment and functions of numerous tissues. C-X-C motif chemokine ligand 12 (CXCL12) has two receptors: C-X-C che-mokine motif receptor 4 (CXCR4) and atypical chemokine re-ceptor 3 (ACKR3). ACKR3 has been described as an atypical "biased" receptor because it does not appear to signal through G proteins and, instead, signals solely through the fl-arrestin pathway. In support of this conclusion, we have shown that ACKR3 is unable to signal through any of the known mamma-lian Ga isoforms and have generated a comprehensive map of the Ga activation by CXCL12/CXCR4. We also synthesized a series of small molecule ligands which acted as selective ago-nists for ACKR3 as assessed by their ability to recruit fl-arrestin to the receptor. Using select point mutations, we studied the molecular characteristics that determine the ability of small molecules to activate ACKR3 receptors, revealing a key role for the deeper binding pocket composed of residues in the trans-membrane domains of ACKR3. The development of more se-lective ACKR3 ligands should allow us to better appreciate the unique roles of ACKR3 in the CXCL12/CXCR4/ACKR3-signal-ing axis and better understand the structural determinants for ACKR3 activation.SIGNIFICANCE STATEMENT We are interested in the signaling produced by the G protein coupled receptor atypical chemokine receptor 3 (ACKR3), which signals atypically. In this study, novel selective ligands for ACKR3 were discovered and the site of interactions be-tween these small molecules and ACKR3 was defined. This work will help to better understand the unique signaling roles of ACKR3.
引用
收藏
页码:128 / 138
页数:11
相关论文
共 50 条
  • [1] Small Molecule Fluorescent Ligands for the Atypical Chemokine Receptor 3 (ACKR3)
    Dekkers, Sebastian
    Comez, Dehan
    Karsai, Noemi
    Arimont-Segura, Marta
    Canals, Meritxell
    Caspar, Birgit
    de Graaf, Chris
    Kilpatrick, Laura E.
    Leurs, Rob
    Kellam, Barrie
    Hill, Stephen J.
    Briddon, Stephen J.
    Stocks, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 15 (01): : 143 - 148
  • [2] ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin
    Saaber, Friederike
    Schuetz, Dagmar
    Miess, Elke
    Abe, Philipp
    Desikan, Srinidhi
    Kumar, Praveen Ashok
    Balk, Sara
    Huang, Ke
    Beaulieu, Jean Martin
    Schulz, Stefan
    Stumm, Ralf
    CELL REPORTS, 2019, 26 (06): : 1473 - +
  • [3] Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model
    Van Loy, Tom
    De Jonghe, Steven
    Castermans, Karolien
    Dheedene, Wouter
    Stoop, Reinout
    Verschuren, Lars
    Versele, Matthias
    Chaltin, Patrick
    Luttun, Aernout
    Schols, Dominique
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (06)
  • [4] Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model
    Tom Van Loy
    Steven De Jonghe
    Karolien Castermans
    Wouter Dheedene
    Reinout Stoop
    Lars Verschuren
    Matthias Versele
    Patrick Chaltin
    Aernout Luttun
    Dominique Schols
    Cellular and Molecular Life Sciences, 2022, 79
  • [5] The Role of ACKR3 in Breast, Lung, and Brain Cancer
    Neves, Maria
    Fumagalli, Amos
    van den Bor, Jelle
    Marin, Philippe
    Smit, Martine J.
    Mayor, Federico
    MOLECULAR PHARMACOLOGY, 2019, 96 (06) : 819 - 825
  • [6] Structural Basis of Nanobody Induced ACKR3 Inhibition
    Schlimgen, Roman
    Peterson, Francis
    Heukers, Raimond
    Smit, Martine
    McCorvy, John
    Volkman, Brian
    FASEB JOURNAL, 2022, 36
  • [7] Characterization of a chimeric chemokine as a specific ligand for ACKR3
    Ameti, Rafet
    Melgrati, Serena
    Radice, Egle
    Cameroni, Elisabetta
    Hub, Elin
    Thelen, Sylvia
    Rot, Antal
    Thelen, Marcus
    JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 104 (02) : 391 - 400
  • [8] Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3)
    Sekiguchi, Haruka
    Kuroyanagi, Tomoko
    Rhainds, David
    Kobayashi, Kazuya
    Kobayashi, Yuka
    Ohno, Hiroaki
    Heveker, Nikolaus
    Akaji, Kenichi
    Fujii, Nobutaka
    Oishi, Shinya
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (08) : 3745 - 3751
  • [9] Conformational Dynamics of Classical and Atypical GPCRs, CXCR4 and ACKR3, by Single-Molecule FRET
    Schafer, Christopher
    Pauszek, Raymond, III
    Gustaysson, Martin
    Handel, Tracy
    Millar, David
    FASEB JOURNAL, 2021, 35
  • [10] Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function
    Cheng, You-Hong
    Eby, Jonathan M.
    LaPorte, Heather M.
    Volkman, Brian F.
    Majetschak, Matthias
    PLOS ONE, 2017, 12 (11):